Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy - PubMed (original) (raw)
J Blankson, J D Siliciano, J B Margolick, K Chadwick, T Pierson, K Smith, J Lisziewicz, F Lori, C Flexner, T C Quinn, R E Chaisson, E Rosenberg, B Walker, S Gange, J Gallant, R F Siliciano
Affiliations
- PMID: 10229227
- DOI: 10.1038/8394
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
D Finzi et al. Nat Med. 1999 May.
Abstract
Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4+ T cells. We measured the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable. The mean half-life of the latent reservoir was very long (43.9 months). If the latent reservoir consists of only 1 x 10(5) cells, eradication could take as long as 60 years. Thus, latent infection of resting CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective anti-retroviral therapy.
Comment in
- HIV-1 and HAART: a time to cure, a time to kill.
Saag MS, Kilby JM. Saag MS, et al. Nat Med. 1999 Jun;5(6):609-11. doi: 10.1038/9452. Nat Med. 1999. PMID: 10371490 No abstract available. - The QUEST trial, a paradigm of HIV collaborative research.
Goh LE, McDade H, Kinloch S, Perrin L, Cooper D, Phillips A, Hoen B, Autran B, Sonnerborg A, Tsoukas C. Goh LE, et al. Nat Med. 2000 Nov;6(11):1194. doi: 10.1038/81251. Nat Med. 2000. PMID: 11062508 No abstract available.
Similar articles
- The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.
Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. Ramratnam B, et al. Nat Med. 2000 Jan;6(1):82-5. doi: 10.1038/71577. Nat Med. 2000. PMID: 10613829 - Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. Zhang L, et al. N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Clinical Trial. - Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T, McArthur J, Siliciano RF. Pierson T, et al. Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review. - Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Chun TW, et al. Nature. 1997 May 8;387(6629):183-8. doi: 10.1038/387183a0. Nature. 1997. PMID: 9144289 - Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.
Plantin J, Massanella M, Chomont N. Plantin J, et al. Retrovirology. 2018 Jan 17;15(1):9. doi: 10.1186/s12977-017-0385-y. Retrovirology. 2018. PMID: 29343255 Free PMC article. Review.
Cited by
- Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation.
Bednar MM, Hauser BM, Zhou S, Jacobson JM, Eron JJ Jr, Frank I, Swanstrom R. Bednar MM, et al. J Infect Dis. 2016 Aug 1;214(3):403-7. doi: 10.1093/infdis/jiw172. Epub 2016 Apr 30. J Infect Dis. 2016. PMID: 27132284 Free PMC article. - Altering cell death pathways as an approach to cure HIV infection.
Badley AD, Sainski A, Wightman F, Lewin SR. Badley AD, et al. Cell Death Dis. 2013 Jul 11;4(7):e718. doi: 10.1038/cddis.2013.248. Cell Death Dis. 2013. PMID: 23846220 Free PMC article. Review. - Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.
Benhar M, Shytaj IL, Stamler JS, Savarino A. Benhar M, et al. J Clin Invest. 2016 May 2;126(5):1630-9. doi: 10.1172/JCI85339. Epub 2016 May 2. J Clin Invest. 2016. PMID: 27135880 Free PMC article. Review. - HIV 2-long terminal repeat circular DNA is stable in primary CD4+T Cells.
Pace MJ, Graf EH, O'Doherty U. Pace MJ, et al. Virology. 2013 Jun 20;441(1):18-21. doi: 10.1016/j.virol.2013.02.028. Epub 2013 Mar 26. Virology. 2013. PMID: 23537959 Free PMC article. - Pharmaceutical Approaches to HIV Treatment and Prevention.
Yavuz B, Morgan JL, Showalter L, Horng KR, Dandekar S, Herrera C, LiWang P, Kaplan DL. Yavuz B, et al. Adv Ther (Weinh). 2018 Oct;1(6):1800054. doi: 10.1002/adtp.201800054. Epub 2018 Jul 29. Adv Ther (Weinh). 2018. PMID: 32775613 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials